Natriuretic Peptide (ANP) vs Ularitide
Your heart's natural fluid and pressure regulator, helping restore balance when fluid overload strikes.
A synthetic natriuretic peptide designed to help your heart pump better and remove excess fluid when you need it most.
Quick comparison
Dose range
Natriuretic Peptide (ANP)
0.025–0.050 mcg/kg/min
Ularitide
15–15 ng/kg/min
Frequency
Natriuretic Peptide (ANP)
Once daily
Ularitide
Once daily
Administration
Natriuretic Peptide (ANP)
Intravenous infusion (continuous) - standard hospital delivery method
Ularitide
Intravenous infusion
Cycle length
Natriuretic Peptide (ANP)
Ongoing/indefinite
Ularitide
Ongoing/indefinite
Onset speed
Natriuretic Peptide (ANP)
Moderate (1-2 weeks)
Ularitide
Moderate (1-2 weeks)
Evidence level
Natriuretic Peptide (ANP)
Moderate human trials (Phase 1-2)
Ularitide
Strong human trials (Phase 3 or FDA approved)
Benefit ratings
Acute Fluid Management
Hemodynamic Stabilization
Symptom Relief
Cardiovascular Support
Fluid & Electrolyte Balance
Kidney Protection
Compound specifications
Natriuretic Peptide (ANP)
Molecular formula
C127H203N45O39S3
Molecular weight
3080.5 g/mol
Half-life
Approximately 15-30 minutes (IV administration)
Bioavailability
100% (intravenous administration)
CAS number
Variable depending on salt form; carperitide CAS: 120399-20-4
Ularitide
Molecular formula
C145H234N52O44S3
Molecular weight
3505.9
Half-life
6-7 minutes (in circulation)
Bioavailability
100% (intravenous administration)
CAS number
Not publicly assigned (proprietary compound)
Dosing compared
Natriuretic Peptide (ANP)
Intravenous
0.0125 mcg/kg/min continuous infusion
Continuous IV infusion · Up to 72 hours
Very low starting dose used in some acute heart failure cases per Japanese Circulation Society guidance [4]. Hospital-only, titrated to blood pressure.
0.025-0.050 mcg/kg/min continuous infusion
Continuous IV infusion · Up to 72 hours
Guideline low-dose range for acute heart failure; associated with better 1-year outcomes than very-low dose [4]. Requires continuous hemodynamic monitoring.
Ularitide
Intravenous infusion
15 ng/kg/min
Continuous infusion · 48 hours
Dose and duration used in the TRUE-AHF trial (2157 patients) for acute heart failure; infusion reduced or stopped for systolic BP <100 mmHg [6]. Investigational only — not an approved drug.
Best suited for
Natriuretic Peptide (ANP)
Managing acute decompensated heart failure with fluid overload
Natriuretic Peptide (ANP) is particularly well-suited for individuals focused on managing acute decompensated heart failure with fluid overload. [8][9] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Relieving shortness of breath caused by pulmonary congestion
Natriuretic Peptide (ANP) is particularly well-suited for individuals focused on relieving shortness of breath caused by pulmonary congestion. [8] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Lowering elevated blood pressure in emergency cardiac situations
Natriuretic Peptide (ANP) is particularly well-suited for individuals focused on lowering elevated blood pressure in emergency cardiac situations. [5][11] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Reducing the workload on the heart during acute episodes
Natriuretic Peptide (ANP) is particularly well-suited for individuals focused on reducing the workload on the heart during acute episodes. [11][12] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Ularitide
Managing acute heart failure symptoms and fluid overload
Ularitide is particularly well-suited for individuals focused on managing acute heart failure symptoms and fluid overload. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1][7].
Improving oxygen delivery when your heart can't pump efficiently
Ularitide is particularly well-suited for individuals focused on improving oxygen delivery when your heart can't pump efficiently. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [7].
Protecting kidney function in critical heart patients
Ularitide is particularly well-suited for individuals focused on protecting kidney function in critical heart patients. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [8].
Side effects
Natriuretic Peptide (ANP)
Common
- Mild discomfort at treatment site
- Hypotension (excessively low blood pressure) requiring close monitoring
- Headache and dizziness from sudden blood pressure changes
- Weakness and fatigue during or shortly after treatment
- Nausea and gastrointestinal discomfort
- Decreased kidney function temporarily, requiring follow-up monitoring
- Tremors or shaking sensations
- Atrial fibrillation (irregular heartbeat) in some patients
- Abdominal pain
- Injection site reactions if administered intravenously
- Renal dysfunction with prolonged use, especially in elderly patients
Serious
- Severe allergic reaction
Ularitide
Common
- Dizziness or lightheadedness
- Low blood pressure (hypotension)
- Headache
- Nausea
Uncommon
- Elevated potassium levels
- Worsening kidney function (transient)
- Allergic reactions at injection site
- Chest discomfort
- Irregular heartbeat (arrhythmia)
Serious
- Severe hypotension requiring intervention
- Worsening heart function in some patients
- Acute kidney injury (rare)
- Anaphylactic shock (very rare)
Safety & evidence
Natriuretic Peptide (ANP)
Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Exogenous ANP demonstrates excellent safety in Phase II/III cardiac decompensation trials with rapid clearance (2-minute half-life) [6][10] providing inherent safety margins. Hypotension is the expected primary effect, managed through continuous hemodynamic monitoring and dose titration. [9][10] No serious adverse events or carcinogenicity observed in 500+ trial participants. Receptor desensitization with prolonged continuous infusion [5] requires periodic treatment breaks or dose adjustments.
Contraindications
- Severe kidney failure with very low glomerular filtration rate
- Recent or ongoing treatment with certain blood pressure medications that may cause dangerous drops in pressure
- Acute coronary syndrome or recent heart attack where vasodilation could be harmful
- Severe hypotension or cardiogenic shock without proper supportive care
- Allergies to ANP, carperitide, or any components of the pharmaceutical formulation
Ularitide
Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
Not FDA approved
Safety overview
Ularitide is a recombinant B-type natriuretic peptide approved in Europe for acute heart failure with safety data from Phase 3 trials showing favorable tolerability compared to placebo and nesiritide. Hypotension is the primary dose-limiting adverse effect, requiring baseline blood pressure assessment and careful hemodynamic monitoring during IV infusion. [6][7][10] Natriuretic peptide class risks include worsening renal function in some patients [6] and hypokalemia (electrolyte abnormalities from enhanced diuresis), necessitating electrolyte monitoring during acute phase therapy.
Contraindications
- Hypotension (dangerously low blood pressure)
- Cardiogenic shock without proper monitoring
- Severe renal dysfunction in some cases
- Allergy to synthetic peptides
Which is right for you?
Choose Natriuretic Peptide (ANP) if...
- Managing acute decompensated heart failure with fluid overload
- Relieving shortness of breath caused by pulmonary congestion
- Lowering elevated blood pressure in emergency cardiac situations
- Reducing the workload on the heart during acute episodes
Choose Ularitide if...
- Managing acute heart failure symptoms and fluid overload
- Improving oxygen delivery when your heart can't pump efficiently
- Protecting kidney function in critical heart patients